---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Prevalence"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Prevalence. Topics: EU prevalence of uveal melanoma at orphan designation of tebentafusp, HLA-A∗02:01 positivity in U.S. and European populations, HLA-A∗02:01 positivity by self-declared race among Brazilian bone marrow donors, HLA-A∗02011 share of HLA-A2 alleles in five U.S. population groups, and 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/prevalence"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Metastatic uveal melanoma

<a id="topic-2.2.1.2.2-1"></a>

### EU prevalence of uveal melanoma at orphan designation of tebentafusp

> “the condition was estimated to be affecting approximately 0.88 in 10,000 persons in the European Union, at the time the application was made.”
> “On average, UM incidence rate of 0.06 per 10,000 inhabitants is estimated for Europe.”
> “Based on this data, a current point prevalence of 0.88 per 10,000 EEA inhabitants was estimated.”

Source: [European Medicines Agency KIMMTRAK orphan maintenance assessment report (2022)](https://www.ema.europa.eu/documents/orphan-maintenance-report/kimmtrak-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

<a id="topic-2.2.1.2.2-2"></a>

### U.S. prevalence of uveal melanoma or of metastatic uveal melanoma

No evidence found.

<a id="topic-2.2.1.2.2-3"></a>

### HLA-A∗02:01 positivity in U.S. and European populations

> “Despite showing unprecedented results, tebentafusp use is restricted to HLA-A*02:01-positivepatients. This accounts for 45% of people in the United States and Europe.”

Source: [de Melo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11299924/)

> “Unfortunately, only 40–50% of the European population express HLA-A*02:01, and eventually, almost all the patients treated with tebentafusp presented disease progression.”

Source: [García-Mulero et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732647/)

<a id="topic-2.2.1.2.2-4"></a>

### HLA-A∗02:01 positivity by self-declared race among Brazilian bone marrow donors

> “Considering the race of the patients tested, 22.5% of white individuals, 17.5% of black, 22.8% of indigenous, 20.4% of yellow, and 20.2% of brown/mixed were HLA-A*02:01-positive.”
> “According to the presented data, the positiveness of HLA-A*02:01 in the Brazilian population is much lower when compared to the frequencies in North Americans and Europeans.”

Source: [de Melo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11299924/)

<a id="topic-2.2.1.2.2-5"></a>

### HLA-A∗02011 share of HLA-A2 alleles in five U.S. population groups

> “The most frequently detected HLA-A2 allele in all groups was HLA-A*02011.”
> “Caucasian and Native American populations appear to be the most homogeneous exhibiting 95.7% and 94.3% A*02011, respectively.”
> “HLA-A*0202 (25.8%) and A*0205 (12.9%) were present in a large percentage of African-Americans.”

Source: [Ellis et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10689125/)

<a id="topic-2.2.1.2.2-6"></a>

### HLA-A∗02:01 frequency in uveal melanoma cohorts compared with the general population

> “As a result, 10 haplotypes showed differences at a FDR of < 0.05 between uveal and population frequencies, of which nine showed higher frequency in uveal melanoma patients: HLA-A*01:01, HLA-A*02:01, HLA-B*08:01, HLA-B*15:01, HLA-B*18:01, HLA-B*44:02, HLA-C*01:02, HLA-C*05:01, HLA-C*07:01, HLA-C*12:03.”

Source: [García-Mulero et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732647/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
